ArticleJournal of clinical medicine2021
Early Experience with the New XEN63 Implant in Primary Open-Angle Glaucoma Patients: Clinical Outcomes.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06844240 (Efficacy and Safety of the XEN63), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of the XEN63: a Prospective Observational Multicenter Study.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Minimally Invasive Bleb Surgery for Glaucoma: A Health Technology Assessment.Ontario health technology assessment series · 2024Pooled it
- Comparison of tube shunt implantation and trabeculectomy for glaucoma: a systematic review and meta-analysis.BMJ open · 2023Pooled it
- Two-years efficacy and safety of bleb forming devices in uncontrolled glaucoma.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Three-Year Outcomes and Safety of the XEN63 Gel Stent: A Multicenter Prospective Study in Primary Open-Angle Glaucoma.Journal of clinical medicine · 2026Article
- Outcomes of Ab Interno 63 µm vs. 45 µm XENJournal of clinical medicine · 2026Article
- Update on XEN Gel Stent: A Narrative Review on Indications, Surgical Technique, and Postoperative Management.Ophthalmology and therapy · 2026Review
- Comparative Outcomes of Standalone Xen63 Gel Stent and Preserflo Microshunt Implantation: A Multicenter Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- XEN63 Gel Stent in Glaucoma: Narrative Review and Expert Perspectives on Patient Selection, Surgical Technique, and Perioperative Management.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Efficacy and Safety of Open-Conjunctiva Ab Externo 63 µm vs. 45 µm XENJournal of clinical medicine · 2025Article
- Efficacy and Safety of Ab Externo Open Conjunctiva XENJournal of clinical medicine · 2025Article
- Efficacy and Safety of XEN63 Gel Stent Implant over 6 Months for Treatment of Glaucoma.Journal of clinical medicine · 2025Article
- Interventional glaucoma: Rethinking glaucoma treatment paradigms in the Asian context.Indian journal of ophthalmology · 2025Review
- Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma.Scientific reports · 2025Article
- Effectiveness and safety of XEN63 in patients with primary-open-angle glaucoma.Scientific reports · 2024Article
- In vivo evaluation of a nanotechnology-based microshunt for filtering glaucoma surgery.Scientific reports · 2024Article
- Effectiveness and Safety of Xen Gel Stent in Glaucoma Surgery: A Systematic Review of the Literature.Journal of clinical medicine · 2023Review
- XENJournal of clinical medicine · 2023Article
- New XEN63 Gel Stent Implantation in Open-Angle Glaucoma: A Two-Year Follow-Up Pilot Study.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Outcomes of XEN 63 Device at 18-Month Follow-Up in Glaucoma Patients: A Two-Center Retrospective Study.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The new XEN63 implant is a minimally invasive glaucoma surgery device with limited experience in real life. This retrospective study included open-angle glaucoma patients who underwent XEN63 implant, either alone or in combination with cataract surgery. Primary endpoints were the intraocular pressure (IOP) at month 3 and the incidence of serious adverse events. Twenty-three eyes of 23 patients were included. Mean age was 67.8 ± 15.3 years and 15 (65.2%) were women. Mean IOP was significantly lowered from 27.0 ± 7.8 mmHg at baseline to 12.2 ± 3.4 mmHg at month 3 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.